Furthermore, recent finding reported that GLP-1 RAs significantly reduced C-reactive protein (CRP) levels in obese IBD patients, alongside a nearly statistically significant reduction in fecal calprotectin (100). This evidence concerns the gene CRP and inflammatory bowel disease.